NCT01717326View on ClinicalTrials.gov

A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035)

PHASE2CompletedINTERVENTIONAL
Enrollment

573

Participants

Timeline

Start Date

February 7, 2013

Primary Completion Date

February 23, 2015

Study Completion Date

May 6, 2015

Conditions
Hepatitis C
Interventions
DRUG

Grazoprevir

100 mg tablet orally QD

DRUG

Elbasvir

Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD

DRUG

Placebo to Elbasvir

Placebo to Elbasvir 20 or 50 mg capsule, orally, once daily for 12 weeks to maintain blind (Part A only)

DRUG

Ribavirin

Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT01717326 - A Study of the Combination Regimen Grazoprevir (MK-5172) and Elbasvir (MK-8742) ± Ribavirin in Participants With Chronic Hepatitis C (MK-5172-035) | Biotech Hunter | Biotech Hunter